These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 3960948)

  • 1. [The in vitro liberation behavior of quinidine from drug forms with prolonged release by various liberation methods].
    Appelt B; Hennig D; Wenzel U
    Pharmazie; 1986 Jan; 41(1):44-6. PubMed ID: 3960948
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Relative bioavailability of various quinidine preparations in man after a single oral dose].
    Terhaag B; Gieszinger U
    Pharmazie; 1982 Dec; 37(12):848-50. PubMed ID: 7163373
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro--in vivo correlation, a time scaling problem? Basic considerations on in vitro dissolution testing.
    Brockmeier D; von Hattingberg HM
    Arzneimittelforschung; 1982; 32(3):248-51. PubMed ID: 6896279
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Relative bioavailability and influence of a quinidine retard-formulation on blood-pressure and ECG in healthy volunteers (author's transl)].
    Knapp W; Lechleitner P
    Arzneimittelforschung; 1981; 31(9):1482-6. PubMed ID: 7197960
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic interactions of nifedipine and quinidine.
    Hippius M; Henschel L; Sigusch H; Tepper J; Brendel E; Hoffmann A
    Pharmazie; 1995 Sep; 50(9):613-6. PubMed ID: 7480098
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Production of delayed-release formulations based on hydrophilic matrix forms using polyvinyl alcohol].
    Süss W
    Pharmazie; 1983 Jul; 38(7):476-8. PubMed ID: 6415679
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Quinidine retard in the prevention of arrhythmias].
    Scébat L; Lenègre J
    Schweiz Rundsch Med Prax; 1971 Sep; 60(38):1255-7. PubMed ID: 5094912
    [No Abstract]   [Full Text] [Related]  

  • 8. Evaluation of a continuous fluid exchange system in the USP basket-stirrer dissolution test assembly. Part 11: Characterization of the dissolution profile of quinidine sustained-release dosage forms.
    Huynh-Ngoc T; Sirois Gérard
    J Pharm Belg; 1977; 32(1):67-75. PubMed ID: 16996
    [No Abstract]   [Full Text] [Related]  

  • 9. Relative bioavailability of a standard and a sustained-release quinidine tablet.
    Gibson DL; Smith GH; Koup JR; Stewart DK
    Clin Pharm; 1982; 1(4):366-8. PubMed ID: 7185532
    [No Abstract]   [Full Text] [Related]  

  • 10. [Possibility of influencing drug release from polymers--using the example of bead polymers].
    Mank R; Kala H
    Pharmazie; 1983 Dec; 38(12):860-4. PubMed ID: 6669615
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The influence of method/apparatus conditions on the in vitro liberation of drugs from suppositories].
    Bornschein M
    Pharmazie; 1986 Dec; 41(12):852-4. PubMed ID: 3575387
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Study of blood quinidine levels obtained by the administration of delayed-action quinidine].
    Renais J; Scebat L; Lenègre J
    Arch Mal Coeur Vaiss; 1971 May; 64(5):701-11. PubMed ID: 4998224
    [No Abstract]   [Full Text] [Related]  

  • 13. A method of determining the in vivo drug release rate constant of sustained-release preparation.
    Sun H; Chow MS
    Drug Metab Dispos; 1995 Apr; 23(4):449-54. PubMed ID: 7600910
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diclofenac sodium multisource prolonged release tablets--a comparative study on the dissolution profiles.
    Bertocchi P; Antoniella E; Valvo L; Alimonti S; Memoli A
    J Pharm Biomed Anal; 2005 Apr; 37(4):679-85. PubMed ID: 15797788
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Control of drug release from coated parenteral matrix-retard tablets using softening agents].
    Korsatko W; Wabnegg B
    Pharmazie; 1983 Sep; 38(9):608-11. PubMed ID: 6647533
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The effect of the solubility of drugs on their liberation from polymethacrylate-coated retard pellets].
    Hennig D; Kala H
    Pharmazie; 1986 Nov; 41(11):814-5. PubMed ID: 3562516
    [No Abstract]   [Full Text] [Related]  

  • 17. [Relationship between quinidine plasma level and clinical effect for a new quinidine retard-formulation (author's transl)].
    Gaul G; Aldor E
    Arzneimittelforschung; 1981; 31(9):1486-8. PubMed ID: 7197961
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Factors influencing liberation of drug from semisolid dosage forms].
    Erös I; Ehab JA; Cserne A; Csóka I; Csányi E
    Acta Pharm Hung; 2000 Apr; 70(2):29-34. PubMed ID: 11192737
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Drug liberation from imbedded forms with a polyacrylate base].
    Dittgen M; Zessin G; Kala H
    Pharmazie; 1977 Dec; 32(12):771-7. PubMed ID: 148660
    [No Abstract]   [Full Text] [Related]  

  • 20. Effect of hydrophilic substances on liberation of quinidine from starch - alginate sphere.
    Kasperek R; Czarnecki W
    Acta Pol Pharm; 2001; 58(2):107-12. PubMed ID: 11501786
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.